Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai acquired 43,150 shares of the stock in a transaction on Wednesday, August 26th. The stock was bought at an average price of $12.26 per share, with a total value of $529,019.00. Following the completion of the acquisition, the director directly owned 707,492 shares of the company's stock, valued at $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Parsa Kiai also recently made the following trade(s):
- On Monday, August 24th, Parsa Kiai acquired 4,329 shares of Medifast stock. The shares were purchased at an average cost of $12.00 per share, for a total transaction of $51,948.00.
- On Thursday, August 20th, Parsa Kiai bought 43,150 shares of Medifast stock. The shares were purchased at an average price of $11.60 per share, for a total transaction of $500,540.00.
- On Wednesday, August 19th, Parsa Kiai bought 29,337 shares of Medifast stock. The shares were purchased at an average price of $11.66 per share, for a total transaction of $342,069.42.
Medifast Stock Performance
Shares of NYSE:MED opened at $12.17 on Friday. The firm has a market capitalization of $136.06 million, a P/E ratio of -5.22 and a beta of 0.65. The stock has a 50 day moving average price of $11.00 and a 200-day moving average price of $11.10. Medifast Inc has a 52-week low of $9.22 and a 52-week high of $14.67.
Medifast (NYSE:MED - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.37. The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. On average, equities analysts forecast that Medifast Inc will post -1.04 EPS for the current fiscal year.
Institutional Trading of Medifast
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Medifast by 30.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer's stock worth $8,297,000 after buying an additional 181,618 shares during the last quarter. Bank of America Corp DE raised its stake in Medifast by 14.2% during the third quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer's stock valued at $6,186,000 after buying an additional 56,174 shares during the last quarter. BlackRock Inc. bought a new stake in Medifast in the second quarter worth $3,920,000. Dimensional Fund Advisors LP boosted its holdings in Medifast by 10.9% in the first quarter. Dimensional Fund Advisors LP now owns 361,762 shares of the specialty retailer's stock worth $3,686,000 after acquiring an additional 35,522 shares in the last quarter. Finally, Lido Advisors LLC purchased a new stake in shares of Medifast in the third quarter worth $4,521,000. Hedge funds and other institutional investors own 95.51% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on MED. Zacks Research downgraded shares of Medifast from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average target price of $12.00.
Read Our Latest Stock Analysis on MED
About Medifast
(
Get Free Report)
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
